Agilis Robotics
About
About Agilis Robotics
Agilis Robotics develops miniature flexible robotic instruments for endoluminal surgery. Devices measuring roughly 2.8 to 3.5 millimetres in diameter and up to 1.8 metres long are designed to travel through natural anatomical pathways and reach tumours in the urinary and gastrointestinal tracts.
The system gives surgeons articulated control beyond the reach of conventional rigid tools, supporting removal of early-stage cancers without external incisions. Agilis combines flexible mechanisms, controls and procedure-specific instruments and is advancing the platform through clinical and regulatory development. Commercial availability will depend on clearance for each intended procedure and market.
Products
Funding
- 2024-03-20 - Series A+ - $10M - Agilis Robotics completes USD 10 million Series A-plus
Agilis Robotics completed a USD 10 million Series A-plus financing round led by a Singapore family office. - source: agilisrobotics.com
- 2022-11-17 - Series A - $6M - Agilis Robotics announces completed USD 6 million Series A
Agilis Robotics announced that it had completed a USD 6 million Series A financing round. - source: agilisrobotics.com
Investors
- Singapore family office - Lead - Unknown - 1 funding event - first seen 2024-03-20
Timeline
Events
- 2026-06-23 - Demonstration - Agilis Robotics conducts live two-site Intilume surgical demonstration
The procedure was performed at Imperial College London's White City laboratory on 23 June 2026. A real-time broadcast connected the laboratory with an audience at the Royal Geographical Society. The demonstration used Intilume for a robot-assisted en-bloc trial and included live coordination and audience questions.
Source - 2025-10-20 - Partnership - Agilis Robotics signs Hong Kong-Jiangsu incubation and investment agreement
The formal signing took place on 20 October 2025 with Suzhou Yuanhe Zhongshan and the Hong Kong Jiangsu center. The center was intended to connect the company with industrial and clinical resources in Jiangsu and the Greater Bay Area. Agilis demonstrated its Intilume system at the center's launch event the following day.
Source - 2025-05-13 - Award - Agilis Robotics system wins China Future Healthcare award
The award recognised the company's smart medical-device technology. Agilis attributed the result to its work on flexible endoscopic surgical robotics. The company continued to position the platform for natural-orifice cancer procedures.
Source - 2024-12-10 - Demonstration - Agilis Robotics completes first robot-assisted en-bloc bladder-tumour resection
The procedure took place on 10 December 2024 at a Hong Kong hospital. A urology team used the company's fully flexible dual-arm endoscopic system through the urethra without an external incision. The system enabled one-piece removal intended to preserve the specimen for pathological analysis and reduce tumour-cell reimplantation risk.
Source - 2024-09-23 - Partnership - Agilis Robotics signs Malaysian purchase-cooperation MOU
Agilis presented its fully flexible endoscopic surgical robot at the Singapore exhibition. The memorandum supported planned product introduction in an overseas market. The company also said its U.S. FDA registration submission had been filed and China and U.S. registration work was proceeding in parallel.
Source - 2024-07-18 - Demonstration - Agilis Robotics completes cadaver study for bladder-tumour resection
Surgeons used the robot to resect tissue in difficult bladder locations including the dome. The system used 2.8-to-3.5-millimetre flexible instruments with five degrees of freedom. Agilis used the study to prepare for a first-in-human clinical investigation and regulatory submissions.
Source - 2024-06-28 - Award - Agilis Robotics receives 2024 Global MedTech Rising Star award
The award was presented on 28 June 2024. The programme recognised emerging medical-device companies for technical innovation and development potential. Agilis was recognised for its fully flexible surgical arms and compatibility with existing hospital endoscopes.
Source - 2024-03-20 - Funding - Agilis Robotics completes USD 10 million Series A-plus
A single Singapore family fund supplied the round. Agilis said the capital would advance product development and clinical registration. The round brought the company's reported cumulative financing above USD 17 million.
Source - 2023-12-27 - Org Change - Agilis Robotics establishes Boston subsidiary
The Boston company was formally established on 27 December 2023. Agilis used the expansion to begin FDA 510(k) work for its endoscopic surgical robot. The company described Boston as a base for overseas medical-institution relationships and market feedback.
Source - 2022-11-17 - Funding - Agilis Robotics announces completed USD 6 million Series A
The company described the financing as its completed A round. Agilis was separately preparing a planned USD 5 million Pre-B round, which is not counted as completed capital here. The company intended to use new financing to support FDA and NMPA regulatory work for its surgical robot.
Source - 2022-09-22 - Demonstration - Agilis Robotics announces successful in vivo bladder-tumour test
The test used robotic arms less than 2.8 millimetres in diameter with conventional urology telescopes and sheaths. The instruments clamped and cut the artificial tumour tissue and removed the tumour in one piece. Agilis positioned the result as a step from prototype and cadaver work toward a first-in-human study.
Source
Relations
Relationships
- Imperial College London
Demonstration Partner - Imperial College London hosted the laboratory side of the live Intilume demonstration.
- The Chinese University of Hong Kong
Clinical Research Partner - Agilis Robotics validated Intilume through clinical trials with the university's urology team.
- Undisclosed Malaysian commercial partner
Commercial Partner - Agilis Robotics signed a purchase-cooperation MOU with a Malaysian commercial partner.
- Hong Kong Jiangsu Innovation and Technology Center
Incubation Partner - The parties signed an investment-incubation cooperation agreement.